Core Points - A class action has been filed against C3.ai, Inc. on behalf of investors who acquired its securities between February 26, 2025, and August 8, 2025, due to allegations of misleading information regarding the CEO's health and its impact on business prospects [1][2] - The complaint highlights that C3.ai did not disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact, leading to concerns about the company's growth and profitability [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health, resulting in a stock price drop of over 25% from $22.13 to $16.47 [3] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by October 21, 2025, with the lead plaintiff representing other class members in the litigation [4] - Shareholders can remain absent class members and are not required to participate in the case to be eligible for recovery [4] Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - The core allegation against C3.ai, Inc. is that the company misled investors regarding the impact of its CEO's health on business prospects, specifically in closing deals and executing growth strategies [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to CEO health problems and management reorganization [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share to $16.47 per share, marking a decline of over 25% [2] Group 2 - A class action has been filed on behalf of individuals and entities that purchased C3.ai securities between February 26, 2025, and August 8, 2025, with a deadline for lead plaintiff submissions set for October 21, 2025 [1][3] - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]

Core Points - A class action has been filed against C3.ai, Inc. on behalf of investors who acquired its securities between February 26, 2025, and August 8, 2025 [1] - Allegations include misleading investors about the impact of the CEO's health on the company's business prospects and its ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year, attributing this to CEO health issues and management reorganization [3] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers by October 21, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Group 1: Allegations and Impact - The lawsuit claims that C3.ai failed to disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by October 21, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Allegations - The complaint claims that during the class period, C3.ai did not disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - It is alleged that C3.ai would struggle to achieve its profit and growth potential due to these undisclosed issues [2]. Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by October 21, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Company Background - Robbins LLP, the firm leading the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].